Drug Overview

SECUKINUMAB is a high-potency BIOLOGIC and a cornerstone IMMUNOMODULATOR within the IMMUNOLOGY drug category. As a TARGETED THERAPY, it is a fully human MONOCLONAL ANTIBODY that selectively binds to and inhibits INTERLEUKIN-17A (IL-17A).

In the landscape of autoimmune treatment, secukinumab was the first-in-class IL-17A inhibitor, providing a sophisticated alternative to older TNF-blockers. By specifically targeting the “effector” cytokine responsible for tissue inflammation rather than broadly suppressing the immune system, it achieves high rates of skin clearance and significant reduction in joint destruction without the same level of systemic suppression seen in multi-pathway drugs.

Generic Name: Secukinumab
US Brand Name: Cosentyx
Drug Class: Interleukin-17A Antagonist; MONOCLONAL ANTIBODY
Route of Administration: Subcutaneous (SC) Injection (Auto-injector/Syringe) or Intravenous (IV) Infusion
FDA Approval Status: FDA-approved for adults and pediatric patients for various inflammatory conditions

Our medical hospital provides expert insights on secukinumab, a trusted IL-17A Inhibitor prescribed for Psoriasis, AS, Psoriatic Arthritis. Find out how this medication improves long-term patient outcomes..

What Is It and How Does It Work? (Mechanism of Action)

SECUKINUMAB image 1 LIV Hospital — secukinumab 2

Secukinumab functions through SELECTIVE CYTOKINE INHIBITION, specifically targeting the IL-17A protein. IL-17A is a naturally occurring cytokine involved in normal immune and inflammatory responses, but it is found in excessively high concentrations in the skin of psoriasis patients and the joints of those with arthritis.

Molecular and Cellular Level Action

The drug interrupts the “IL-23/IL-17 axis,” which is the primary driver of autoimmune tissue damage:

High-Affinity Binding: Secukinumab binds directly to the IL-17A cytokine, preventing it from attaching to the IL-17 receptors on the surface of target cells (such as keratinocytes in the skin or synoviocytes in the joints).
Inhibition of Pro-inflammatory Release: By blocking this connection, the drug stops the cells from releasing secondary inflammatory chemicals, such as IL-6, metalloproteinases, and chemokines.
Halting Neutrophil Recruitment: IL-17A is a major signal for recruiting neutrophils to tissues. Secukinumab reduces this influx, which rapidly decreases redness, swelling, and “pus-like” (pustular) activity in skin lesions.
Prevention of Systemic Damage: In the joints, secukinumab inhibits the activation of osteoclasts (cells that eat bone), thereby halting the permanent systemic damage and erosions characteristic of Ankylosing Spondylitis and Psoriatic Arthritis.

FDA-Approved Clinical Indications

Primary Indications

Plaque Psoriasis: Moderate-to-severe disease in adults and pediatric patients (6+ years) who are candidates for systemic therapy or phototherapy.
Psoriatic Arthritis (PsA): Adult and pediatric patients (2+ years) with active disease.
Ankylosing Spondylitis (AS): Active disease in adults.
Non-radiographic Axial Spondyloarthritis (nr-axSpA): Active disease in adults with objective signs of inflammation.
Enthesitis-Related Arthritis (ERA): Pediatric patients (4+ years) with active disease.
Hidradenitis Suppurativa (HS): Moderate-to-severe disease in adults (Approved in 2023–2024).

Other Approved & Off-Label Uses

Uveitis: Sometimes explored in refractory cases of non-infectious uveitis associated with spondyloarthritis.
Giant Cell Arteritis: Under investigation for its role in reducing blood vessel inflammation.

Dosage and Administration Protocols

Secukinumab is typically administered as a SUBCUTANEOUS INJECTION. Maintenance dosing is remarkably convenient, often requiring only one injection per month.

Indication	Induction (Loading)	Maintenance
Plaque Psoriasis (Adult)	300 mg at Weeks 0, 1, 2, 3, and 4	300 mg Every 4 Weeks
Psoriatic Arthritis	150 mg or 300 mg at Weeks 0–4	150 mg or 300 mg Every 4 Weeks
Ankylosing Spondylitis	150 mg at Weeks 0–4	150 mg Every 4 Weeks
Hidradenitis Suppurativa	300 mg at Weeks 0–4	300 mg Every 4 Weeks (up to every 2)

Clinical Notes:

IV Loading: As of 2024–2026, an IV loading option is available for certain patients to achieve rapid therapeutic levels.
Storage: Must be refrigerated. Let the pen reach room temperature for 15–30 minutes before injecting to reduce stinging.

Clinical Efficacy and Research Results

Clinical trials (the ERASURE, FIXTURE, and MEASURE studies) established secukinumab as a high-performance biologic.

Numerical Research Data

Psoriasis Clearance: In trials, up to 80% of patients achieved PASI 75 (75% skin clearance) by week 12. Impressively, roughly 40% to 50% achieved PASI 100 (completely clear skin).
Joint Preservation: In PsA and AS, secukinumab showed a significant reduction in the Modified Total Sharp Score (mTSS), proving that it physically slows the progression of joint damage compared to placebo.
HS Response: 2024–2026 real-world data shows that over 50% of patients with Hidradenitis Suppurativa see a meaningful reduction in abscesses and inflammatory nodules.

Recent Research (2025–2026)

Current research in PRECISION IMMUNOLOGY focuses on the “Skin-Joint-Gut” connection. Studies in 2026 are looking at whether early use of secukinumab in psoriasis patients can actually prevent the future development of Psoriatic Arthritis by calming enthesitis (inflammation where tendons meet bone) before it becomes symptomatic.

Disclaimer: The research discussed regarding the potential for preventing psoriatic arthritis via early enthesitis treatment and the investigation into secukinumab for giant cell arteritis is currently in the investigational or early-phase clinical trial stage and is not yet applicable to practical or professional clinical scenarios.

Safety Profile and Side Effects

Secukinumab is generally well-tolerated, with a safety profile focused on mucosal defenses.

Common Side Effects (>10%)

Nasopharyngitis: Increased frequency of the common cold or sore throat.
Upper Respiratory Infections: Sinusitis or rhinitis.
Diarrhea: Usually mild.

Serious Adverse Events & Precautions

Infections: Slight increase in the risk of Candidiasis (Yeast/Thrush). Because IL-17 is vital for fighting fungal infections, patients may experience thrush in the mouth or genital area.
Inflammatory Bowel Disease (IBD): Caution. Secukinumab can worsen or trigger new cases of Crohn’s Disease or Ulcerative Colitis. Patients with a history of IBD must be monitored closely or avoid this class of drugs.
Tuberculosis (TB): Patients must be screened for TB before starting, although the risk of reactivation is lower than with TNF-blockers.

Patient Management and Do’s and Don’ts

Do’s

DO rotate your injection sites (thighs, abdomen, or upper arms) to prevent skin hardening.
DO notify your doctor if you develop a “cottage cheese” like coating in your mouth (thrush).
DO ensure you are up to date on non-live vaccines (Flu, COVID-19, Shingrix) before starting.

Don’ts

DON’T receive “live” vaccines (like Yellow Fever or MMR) while on therapy.
DON’T use the medication if you notice a sudden change in bowel habits, bloody stools, or severe abdominal pain (signs of IBD).
DON’T shake the pen or syringe; this can damage the delicate proteins in the BIOLOGIC.

Legal Disclaimer

This guide is for informational purposes only and does not substitute for professional medical advice. SECUKINUMAB must be managed by a qualified Dermatologist or Rheumatologist. Always consult with your healthcare provider regarding the risks and benefits of IL-17A INHIBITOR therapy. Never disregard professional medical advice based on information provided in this guide. Proper disposal of needles in a Sharps container is mandatory for home use.